Stock THAR THARIMMUNE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tharimmune, Inc.

Equities

THAR

US4327052001

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/05/2024 BST 		5-day change 1st Jan Change
0.361 USD -1.98% Intraday chart for Tharimmune, Inc. -4.01% -29.08%
05-09 Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-23 Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates CI

Valuation

Fiscal Period: December 2023 2024 2025
Capitalization 1 1.285 4.255 -
Enterprise Value (EV) 1 1.285 4.255 4.255
P/E ratio -0.07 x - -
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA - - -
EV / FCF - - -
FCF Yield - - -
Price to Book - - -
Nbr of stocks (in thousands) 2,525 11,786 -
Reference price 2 0.5090 0.3610 0.3610
Announcement Date 23/02/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2023 2024 2025
Net sales 1 - - - -
EBITDA - - - -
EBIT 1 - - -12 -14.5
Operating Margin - - - -
Earnings before Tax (EBT) - - - -
Net income -2.207 -9.319 - -
Net margin - - - -
EPS -8.750 -7.140 - -
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 01/04/22 23/02/24 - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2023 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 01/04/22 23/02/24 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.361 USD
Average target price
5 USD
Spread / Average Target
+1,285.04%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
THARIMMUNE, INC. Stock Tharimmune, Inc.
-29.08% 4.25M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 106B
ARGENX SE Stock argenx SE
-2.62% 21.96B
BIONTECH SE Stock BioNTech SE
-14.15% 21.87B
GENMAB A/S Stock Genmab A/S
-5.29% 19.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 18.08B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 17.71B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 14.32B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 12.42B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. THAR Stock
  4. Financials Tharimmune, Inc.